TPSTBullishTempest exercises option to license Senlang CD7 lentiviral platformnews
Medium materiality6/10
Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
Nov 11, 2026, 9:40 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The license expands Tempest’s delivery capabilities and pipeline, potentially increasing future commercializable product opportunities and revenue streams if clinical development succeeds; the near‑term impact depends on confirmation of efficacy/safety and development timelines.
AI summary
What happened, with direct paths to the underlying reporting
Tempest exercised its option to license Senlang’s CD7-targeted lentiviral in vivo CAR‑T platform (exclusive outside China) after preliminary DELIVER‑1 Phase 1 observations with lead dual‑targeting TPST‑4903 in 13 rrMM patients.
Tempest exercised its option to obtain an exclusive license to Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR‑T candidates worldwide, excluding China.
At data cutoff, 13 patients in the DELIVER-1 Phase 1 study had received TPST‑4903 and Tempest described preliminary clinical activity and tolerability as encouraging.
The licensed platform and pipeline include additional clinical and preclinical in vivo CAR‑T candidates for blood cancers, solid tumors, and autoimmune conditions.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
